The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Sawyer, T E ^a   Bonner, J A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Camptothecin; Cell cycle distribution; Glutathione depletion; V79 cells

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BUTHIONINE SULFOXIMINE; DNA TOPOISOMERASE; GLUTATHIONE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; ENZYME INHIBITOR;

ANIMAL CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN V 79; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DNA PROTEIN COMPLEX; DRUG ACCUMULATION; DRUG SENSITIVITY; HAMSTER; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ARTICLE; CELL CULTURE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BUTHIONINE SULFOXIMINE; CAMPTOTHECIN; CELL SURVIVAL; CELLS, CULTURED; CRICETINAE; DNA TOPOISOMERASES, TYPE I; DRUG INTERACTIONS; ENZYME INHIBITORS; GLUTATHIONE;

EID: 0029888732     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. ALLER P, RIUS C, MATA F, ZORRILLA A, CABANAS C, BELLON T AND BERNABEU C. (1992). Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res., 52, 1245-1251.
2. BONNER JA, CHRISTIANSON TJH AND LAWRENCE TS. (1992). Interaction of buthionine sulfoximide and the stabilization of DNA-topoisomeruse II complexes by doxorubicin. Int. J. Radiat. Oncol. Biol. Phys., 22, 519-523.
3. BONNER JA, MAIHLE NJ, FOLVEN BR, CHRISTIANSON TJH AND SPAIN K. (1994). The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int. J. Radiat. Oncol. Biol. Phys., 29, 243-247.
4. CHASSEAUD LF. (1979). The role of glutathione and glutathione s-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv. Cancer Res., 29, 175-275.
5. CRISSMAN HA AND STEINKAMP JA. (1982). Rapid, one step staining procedures for analysis of cellular DNA and protein by single and dual laser flow cytometry. Cytometry, 3, 84-90.
6. DUSRE L, MIMNAUGH EG, MYERS CE AND SINHA BK. (1989). Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res., 49, 511-515.
7. LAI GM, OZOLS RF, YOUNG RC AND HAMILTON TC. (1989). Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J. Natl Cancer Inst., 81, 535-539.
8. MINEHAN KJ AND BONNER JA. (1993). The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment. Life Sciences, 53, 237-242.
9. NIIMI S, NAKAGAWA K, SUGIMOTO Y, NISHIO K, FUJIWARA Y, YOKOYAMA S, TERASHIMA Y AND SAIJO N. (1992). Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res., 52, 328-333.
10. POMMIER Y AND TANIZAWA A. (1993) Mammalian DNA topoisomerase I and its inhibitors. In Cancer Chemotherapy Hickman J, Tritton T. (eds). pp. 214-250. Blackwell: Oxford.
11. RICE GC, BUMP EA, SHRIEVE DC, LEE W AND KOVACS M. (1986). Quantitative analysis of cellular glutathione by flow cytometry utilizing monochlorobimane: Some applications to radiation and drug resistance in vitro and in vivo. Cancer Res., 46, 6105-6110.
12. SCHAAK J, SCHEDL P AND SHENK T. (1990). Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function. Nucleic Acids Res., 18, 1499-1508.
13. SCHNEIDER E, YAMAZAKI H, SINHA BK AND COWAN KH (1995). Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpression the multidrug resistance-associated protein involves increased drug accumulation. Br. J. Cancer, 71, 738-743.
14. SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC AND KAUFMANN SH. (1993). The current status of camptothecin analogues as antitumor agents. J. Natl Cancer Inst., 85, 271-291.
15. TANIZAWA A, FUJIMORI A, FUJIMORI Y AND POMMIER Y. (1994). Comparison of topisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl Cancer Inst., 86, 836-842.
16. ZHANG H, WANG JC AND LIU L. (1988). Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl Acad. Sci. USA, 85, 1060-1064.